Annual total expenses:
$6.63B+$1.06B(+19.12%)Summary
- As of today (August 23, 2025), VRTX annual total expenses is $6.63 billion, with the most recent change of +$1.06 billion (+19.12%) on December 31, 2024.
- During the last 3 years, VRTX annual total expenses has risen by +$1.83 billion (+38.16%).
- VRTX annual total expenses is now at all-time high.
Performance
VRTX Total expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly total expenses:
$1.95B-$146.70M(-6.99%)Summary
- As of today (August 23, 2025), VRTX quarterly total expenses is $1.95 billion, with the most recent change of -$146.70 million (-6.99%) on June 30, 2025.
- Over the past year, VRTX quarterly total expenses has dropped by -$4.28 billion (-68.64%).
- VRTX quarterly total expenses is now -68.64% below its all-time high of $6.23 billion, reached on June 30, 2024.
Performance
VRTX Quarterly total expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Total expenses Formula
Total Expenses = Cost of Goods Sold + Operating Expenses + Non Operating Expenses
VRTX Total expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +19.1% | -68.6% |
| 3 y3 years | +38.2% | +45.7% |
| 5 y5 years | +123.8% | +186.9% |
VRTX Total expenses Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +45.1% | -68.6% | +45.9% |
| 5 y | 5-year | at high | +123.8% | -68.6% | +186.9% |
| alltime | all time | at high | >+9999.0% | -68.6% | +384.6% |
VRTX Total expenses History
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2025 | - | $1.95B(-7.0%) |
| Mar 2025 | - | $2.10B(+6.3%) |
| Dec 2024 | $6.63B(+19.1%) | $1.97B(+14.2%) |
| Sep 2024 | - | $1.73B(-72.2%) |
| Jun 2024 | - | $6.23B(+292.3%) |
| Mar 2024 | - | $1.59B(+2.3%) |
| Dec 2023 | $5.56B(+21.8%) | $1.55B(+7.4%) |
| Sep 2023 | - | $1.45B(-7.9%) |
| Jun 2023 | - | $1.57B(-5.1%) |
| Mar 2023 | - | $1.65B(+15.5%) |
| Dec 2022 | $4.57B(-4.8%) | $1.43B(+6.9%) |
| Sep 2022 | - | $1.34B(-0.2%) |
| Jun 2022 | - | $1.34B(+1.9%) |
| Mar 2022 | - | $1.32B(+1.7%) |
| Dec 2021 | $4.80B(+43.7%) | $1.29B(+13.7%) |
| Sep 2021 | - | $1.14B(-34.8%) |
| Jun 2021 | - | $1.74B(+60.3%) |
| Mar 2021 | - | $1.09B(+5.1%) |
| Dec 2020 | $3.34B(+12.7%) | $1.04B(+17.9%) |
| Sep 2020 | - | $878.09M(+29.0%) |
| Jun 2020 | - | $680.85M(-24.6%) |
| Mar 2020 | - | $903.43M(+9.8%) |
| Dec 2019 | $2.96B(+24.2%) | $822.87M(-6.7%) |
| Sep 2019 | - | $882.01M(+32.5%) |
| Jun 2019 | - | $665.63M(+14.2%) |
| Mar 2019 | - | $582.97M(-184.9%) |
| Dec 2018 | $2.38B(+13.7%) | -$686.27M(-204.9%) |
| Sep 2018 | - | $654.08M(+19.5%) |
| Jun 2018 | - | $547.54M(+27.1%) |
| Mar 2018 | - | $430.63M(-21.9%) |
| Dec 2017 | $2.10B(+23.9%) | $551.04M(-19.1%) |
| Sep 2017 | - | $681.12M(+29.9%) |
| Jun 2017 | - | $524.19M(+12.2%) |
| Mar 2017 | - | $467.37M(+9.8%) |
| Dec 2016 | $1.69B(+13.0%) | $425.76M(-5.9%) |
| Sep 2016 | - | $452.62M(-8.8%) |
| Jun 2016 | - | $496.13M(+12.8%) |
| Mar 2016 | - | $439.71M(-10.9%) |
| Dec 2015 | $1.50B(+22.5%) | $493.45M(+21.8%) |
| Sep 2015 | - | $404.96M(+14.1%) |
| Jun 2015 | - | $354.92M(+5.3%) |
| Mar 2015 | - | $337.12M(+5.0%) |
| Dec 2014 | $1.22B(-10.7%) | $321.00M(-8.0%) |
| Sep 2014 | - | $348.98M(+17.2%) |
| Jun 2014 | - | $297.80M(-15.1%) |
| Mar 2014 | - | $350.91M(+14.3%) |
| Dec 2013 | $1.37B(-7.4%) | $306.87M(-11.3%) |
| Sep 2013 | - | $345.83M(-6.0%) |
| Jun 2013 | - | $367.92M(-42.2%) |
| Mar 2013 | - | $636.38M(+55.2%) |
| Dec 2012 | $1.48B(+24.4%) | $410.14M(+4.2%) |
| Sep 2012 | - | $393.55M(-18.6%) |
| Jun 2012 | - | $483.24M(+38.8%) |
| Mar 2012 | - | $348.05M(-14.1%) |
| Dec 2011 | $1.19B(+41.9%) | $405.00M(-8.0%) |
| Sep 2011 | - | $440.23M(+52.6%) |
| Jun 2011 | - | $288.49M(+15.5%) |
| Mar 2011 | - | $249.76M(+1.6%) |
| Dec 2010 | $837.95M(+20.6%) | $245.92M(+5.7%) |
| Sep 2010 | - | $232.75M(+0.5%) |
| Jun 2010 | - | $231.63M(+23.4%) |
| Mar 2010 | - | $187.70M(-2.5%) |
| Dec 2009 | $694.67M(+9.6%) | $192.53M(+10.3%) |
| Sep 2009 | - | $174.52M(-8.3%) |
| Jun 2009 | - | $190.36M(+2.0%) |
| Mar 2009 | - | $186.65M(+6.6%) |
| Dec 2008 | $633.89M | $175.14M(+8.3%) |
| Sep 2008 | - | $161.65M(+0.6%) |
| Jun 2008 | - | $160.73M(+16.6%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2008 | - | $137.83M(+0.8%) |
| Dec 2007 | $611.68M(+38.5%) | $136.74M(-7.6%) |
| Sep 2007 | - | $148.05M(-5.1%) |
| Jun 2007 | - | $155.96M(+4.3%) |
| Mar 2007 | - | $149.54M(+23.0%) |
| Dec 2006 | $441.74M(+46.0%) | $121.60M(+15.7%) |
| Sep 2006 | - | $105.09M(-2.1%) |
| Jun 2006 | - | $107.38M(+19.0%) |
| Mar 2006 | - | $90.22M(-11.5%) |
| Dec 2005 | $302.63M(+26.1%) | $101.89M(-12.0%) |
| Sep 2005 | - | $115.78M(+57.9%) |
| Jun 2005 | - | $73.31M(-0.0%) |
| Mar 2005 | - | $73.33M(-11.2%) |
| Dec 2004 | $239.95M(-0.8%) | $82.60M(+25.9%) |
| Sep 2004 | - | $65.60M(+4.4%) |
| Jun 2004 | - | $62.81M(+8.4%) |
| Mar 2004 | - | $57.95M(-6.1%) |
| Dec 2003 | $241.84M(-0.4%) | $61.73M(-41.1%) |
| Sep 2003 | - | $104.77M(-2.5%) |
| Jun 2003 | - | $107.50M(+5280.6%) |
| Mar 2003 | - | $2.00M(-97.4%) |
| Dec 2002 | $242.73M(+21.1%) | $75.87M(+12.0%) |
| Sep 2002 | - | $67.73M(+6.9%) |
| Jun 2002 | - | $63.35M(+0.9%) |
| Mar 2002 | - | $62.76M(-3.6%) |
| Dec 2001 | $200.40M(+5.1%) | $65.13M(-6.4%) |
| Sep 2001 | - | $69.60M(+107.4%) |
| Jun 2001 | - | $33.55M(+20.1%) |
| Mar 2001 | - | $27.93M(+457.9%) |
| Dec 2000 | $190.72M(+88.5%) | $5.01M(-87.1%) |
| Sep 2000 | - | $38.72M(+58.6%) |
| Jun 2000 | - | $24.42M(+3.1%) |
| Mar 2000 | - | $23.68M(-5.8%) |
| Dec 1999 | $101.20M(+31.6%) | $25.14M(+16.9%) |
| Sep 1999 | - | $21.51M(-7.9%) |
| Jun 1999 | - | $23.36M(+8.6%) |
| Mar 1999 | - | $21.52M(+4.5%) |
| Dec 1998 | $76.90M(+22.1%) | $20.60M(+21.8%) |
| Sep 1998 | - | $16.91M(+29.6%) |
| Jun 1998 | - | $13.05M(+12.6%) |
| Mar 1998 | - | $11.59M(-34.5%) |
| Dec 1997 | $63.00M(+8.4%) | $17.70M(-7.8%) |
| Sep 1997 | - | $19.20M(+43.3%) |
| Jun 1997 | - | $13.40M(+7.2%) |
| Mar 1997 | - | $12.50M(-50.6%) |
| Dec 1996 | $58.10M(+19.5%) | $25.30M(+145.6%) |
| Sep 1996 | - | $10.30M(-9.6%) |
| Jun 1996 | - | $11.40M(+2.7%) |
| Mar 1996 | - | $11.10M(+5.7%) |
| Dec 1995 | $48.60M(+20.6%) | $10.50M(+1.9%) |
| Sep 1995 | - | $10.30M(-38.7%) |
| Jun 1995 | - | $16.80M(+52.7%) |
| Mar 1995 | - | $11.00M(-0.9%) |
| Dec 1994 | $40.30M(+50.9%) | $11.10M(+7.8%) |
| Sep 1994 | - | $10.30M(+1.0%) |
| Jun 1994 | - | $10.20M(+15.9%) |
| Mar 1994 | - | $8.80M(-6.4%) |
| Dec 1993 | $26.70M(+93.5%) | $9.40M(+28.8%) |
| Sep 1993 | - | $7.30M(+30.4%) |
| Jun 1993 | - | $5.60M(+27.3%) |
| Mar 1993 | - | $4.40M(+12.8%) |
| Dec 1992 | $13.80M(+56.8%) | $3.90M(+8.3%) |
| Sep 1992 | - | $3.60M(+9.1%) |
| Jun 1992 | - | $3.30M(+10.0%) |
| Mar 1992 | - | $3.00M(+20.0%) |
| Dec 1991 | $8.80M(+37.5%) | $2.50M(+13.6%) |
| Sep 1991 | - | $2.20M(+4.8%) |
| Jun 1991 | - | $2.10M |
| Dec 1990 | $6.40M | - |
FAQ
- What is Vertex Pharmaceuticals Incorporated annual total expenses?
- What is the all time high annual total expenses for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated annual total expenses year-on-year change?
- What is Vertex Pharmaceuticals Incorporated quarterly total expenses?
- What is the all time high quarterly total expenses for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated quarterly total expenses year-on-year change?
What is Vertex Pharmaceuticals Incorporated annual total expenses?
The current annual total expenses of VRTX is $6.63B
What is the all time high annual total expenses for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high annual total expenses is $6.63B
What is Vertex Pharmaceuticals Incorporated annual total expenses year-on-year change?
Over the past year, VRTX annual total expenses has changed by +$1.06B (+19.12%)
What is Vertex Pharmaceuticals Incorporated quarterly total expenses?
The current quarterly total expenses of VRTX is $1.95B
What is the all time high quarterly total expenses for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high quarterly total expenses is $6.23B
What is Vertex Pharmaceuticals Incorporated quarterly total expenses year-on-year change?
Over the past year, VRTX quarterly total expenses has changed by -$4.28B (-68.64%)